Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nestorone and testosterone gel for male contraception
2016-002498-36Phase 2Completed
- Sponsor
- National Institutes of Health
- Start
- Aug 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of segesterone and testosterone in contraception (2 arms), sponsored by National Institutes of Health. Primary endpoint: Twelve-month cumulative contraceptive efficacy. Started Aug 2018; status: completed.
02
Drugs
segesteronetestosterone
03
Conditions
contraception
Beyond the preview
Go deeper on 2016-002498-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002498-36.